Core Viewpoint - The report from Shenwan Hongyuan indicates that Zai Lab (09688) is expected to achieve non-GAAP operating profit by Q4 2025, driven by the commercialization of products and localized production [1] Financial Projections - Revenue projections for Zai Lab from 2025 to 2027 are estimated at $553 million, $802 million, and $1.203 billion respectively, with net profit attributable to the parent company expected to be -$134 million, $15 million, and $173 million for the same years [1] - The target price set at HKD 35.2 implies a 39% upside potential, reflecting confidence in the company's innovative pipeline [1] Product Portfolio and Commercialization - Zai Lab is a global biopharmaceutical company in the commercialization stage, with seven products approved in China, including four oncology products and one immunology product [2] - Since the approval of its first commercial product, Niraparib, in 2019, Zai Lab has seen significant sales growth, with total revenue projected to reach $399 million in 2024, a 50% increase year-on-year [3] New Product Development - The company has submitted applications for new products, including KarXT and TF ADC, to the NMPA, with plans to submit for Bemarituzumab for 1L gastric cancer in the second half of the year [3] - Zai Lab anticipates revenue could reach $2 billion by 2028, supported by the sales of existing products and the approval of new products [3] Expansion of Indications - Efgartigimod, the first FcRn antagonist globally, has received approvals for multiple indications, with sales expected to reach $94 million in 2024, reflecting an 835% year-on-year growth [4] - The company is exploring additional indications for Efgartigimod, which could broaden its market reach across various medical fields [4] Global Pipeline Development - Zai Lab is actively expanding its global pipeline, focusing on ADCs and bispecific antibodies, with several products showing potential for first-in-class (FIC) or best-in-class (BIC) status [5] - The company plans to initiate global pivotal studies for ZL-1310, which has shown promising clinical activity and safety [5]

Core Viewpoint - Zai Ding Pharma is expected to achieve non-GAAP operating profit by Q4 2025, driven by the commercialization of products and localized production [1] Financial Projections - Revenue projections for Zai Ding Pharma are $553 million, $802 million, and $1.203 billion for 2025, 2026, and 2027 respectively [1] - Net profit projections for the company are -$134 million, $15 million, and $173 million for 2025, 2026, and 2027 respectively [1] - The target price is set at HKD 35.2, indicating a potential upside of 39% [1] Product Portfolio and Pipeline - Zai Ding Pharma has seven products approved for sale in China, including four oncology products, one immunology product, and two infectious disease products [2] - The company has seen a 50% year-on-year revenue growth in 2024, reaching $399 million, primarily due to the sales increase of existing products [3] - New product applications have been submitted to NMPA, with expectations for further approvals in the near future [3] Key Product Developments - Efgartigimod (艾加莫德) is being explored for additional indications beyond its current approvals, with significant sales growth anticipated [4] - The product is expected to generate $94 million in domestic sales in 2024, reflecting an 835% increase [4] Global Pipeline Expansion - The company is actively expanding its global pipeline, focusing on ADCs and bispecific antibodies [5] - ZL-1310 has received Fast Track designation from the FDA, with positive clinical data expected to be presented at the 2025 ASCO annual meeting [5] - The company plans to initiate global pivotal studies for ZL-1310 in the near future [5]

Core Viewpoint - The report from Shenwan Hongyuan indicates that Sunshine Insurance (06963) is expected to see a steady growth in net profit from 2025 to 2027, with projected figures of 5.734 billion, 6.056 billion, and 6.788 billion yuan respectively, reflecting year-on-year growth rates of 5.2%, 5.6%, and 12.1% [1] Group 1: Profit Growth and Dividend Policy - The company is projected to achieve a year-on-year net profit increase of 45.8% to 5.449 billion yuan in 2024, with a stable profit performance in the first half of 2025, showing a year-on-year growth of 7.8% to 3.389 billion yuan [2] - The dividend payout ratio is expected to reach 40.1% in 2024, ranking first among listed insurance companies, with a calculated dividend yield of 5.4% based on the closing price on September 22, placing it second in the industry [2] Group 2: New Business Value (NBV) and Distribution Channels - The company has demonstrated strong resilience and growth in its life insurance segment, with NBV growth rates of 44.2% and 43.3% for 2023 and 2024 respectively, and a year-on-year increase of 47.3% to 4.008 billion yuan in the first half of 2025, leading the industry [3] - The bancassurance channel remains a traditional strength for the company, benefiting significantly from the "reporting and operation integration," with channel NBV growth rates of 6.4 percentage points and 7.2 percentage points for 2024 and the first half of 2025 respectively [3] Group 3: Liability Costs and Investment Returns - The company has seen a significant decline in new liability costs, with the NBV to effective business value ratio at 12.79% in 2024, ranking third among listed insurance companies, which is expected to further dilute the cost of existing liabilities [4] - The net investment return rate and the difference between NBV and effective business value yield are projected to increase year-on-year by 100 basis points and 31 basis points respectively, indicating an expansion of the interest spread [4] Group 4: Equity Allocation and Performance Stability - As of the end of June, the company's equity allocation in the secondary market has increased by 1.28 percentage points to 15.1%, with a stock allocation level that continues to rise, reaching 14.1% by the end of 2024, and the proportion of FVOCI stocks exceeding 70.38% [5] - The company’s CSM has shown steady growth, with a year-on-year increase of 12.6% to 50.9 billion yuan by the end of 2024, maintaining a stable amortization rate of 8.45% [5]

Group 1 - The announcement from Guozhong Water indicated a change in the sponsor representative for its ongoing issuance supervision work, with Shenwan Hongyuan now responsible for this role [2] - The new sponsor representatives are Mr. Zhao Zhidan and Mr. Cai Ming [2] - This change is part of the company's efforts to ensure compliance and effective management of its issuance process [2]

为深入贯彻落实国家金融监督管理总局指导下开展金融宣传周活动，坚持以人民为中心的价值取向，不 断提升金融消费者和投资者风险识别和防范能力，大力培育和弘扬"诚实守信、以义取利、稳健审慎、 守正创新、依法合规"的中国特色金融文化，国家金融监督管理总局新疆监管局、中国人民银行新疆维 吾尔自治区分行、中国证券监督管理委员会新疆监管局指导，深圳证券交易所与申万宏源证券新疆（乌 鲁木齐）投资者教育基地共同展开"保障金融权益，助力美好生活"金融教育宣传周系列活动。 第一站——金融教育宣传周系列活动走进证券营业部 9月16日，"保障金融权益，助力美好生活"主题活动首站，在申万宏源西部证券乌鲁木齐北京中路证券 营业部正式拉开帷幕。60余名投资者与深交所投资者服务部讲师齐聚现场，开始展开深入交流探讨。活 动中，深交所投资者服务部资深讲师凭借专业知识与实践经验，以通俗易懂的语言结合鲜活案例，为投 资者详细解读当前金融市场形势、投资风险防范要点，以及各类金融产品的特点与选择策略。投资者全 程专注聆听，不时提出关心的金融问题，讲师均耐心细致解答，现场互动氛围热烈。ETF交易成为活动 后投资者相互交流的高频话题。不少投资者表示，此前对ET ...

Core Viewpoint - The 2025 Financial Education Promotion Week aims to enhance financial consumers' and investors' ability to identify and prevent risks, with a focus on safeguarding financial rights and improving quality of life [1][3]. Group 1: Event Overview - The event was held on September 15, organized by various financial regulatory bodies and associations in Xinjiang, with significant participation from the banking, insurance, and securities sectors [1][3]. - A total of 28 banking institutions, 25 insurance companies, and 10 securities firms participated, engaging over 500 investors in interactive activities [3]. Group 2: Educational Activities - The Shenyuan Hongyuan Securities Xinjiang Investor Education Base played a key role in the event, incorporating interactive and educational elements to make financial education more accessible [3][6]. - Activities included games like "Anti-Fraud Wheel" and "Investment Education Puzzle," designed to teach investors about identifying illegal securities activities and understanding their rights [3][6]. Group 3: Investor Engagement - Investors expressed that the "game + science popularization" approach was more engaging than traditional presentations, helping them remember key concepts about identifying fraudulent platforms and seeking help from legitimate institutions [6]. - The education base also provided one-on-one consultation services to address specific investor inquiries regarding compliance checks and risk prevention strategies [6][15]. Group 4: Future Initiatives - The education base plans to continue innovating educational formats and content to meet investor needs, aiming to enhance investor literacy and protect their rights in the financial market [15].

Group 1 - The total trading volume of the two markets reached 2.44 trillion yuan, an increase of 372.9 billion yuan compared to the previous day [2] - The net inflow of funds into the top three industries (according to Shenwan's first-level classification) includes: Banking (2.023 billion yuan), Power Equipment (4.519 billion yuan), and Automotive (3.400 billion yuan) [2] - The market is expected to maintain a range-bound fluctuation between 3700 and 3900 points in the short term, driven by profit-taking ahead of the holiday [2] Group 2 - The A50 ETF by Huabao focuses on the top 50 core leading companies, providing investors with a diversified option to invest in China [2] - The MACD golden cross signal has formed, indicating a positive trend for certain stocks [4]

Group 1 - The company, Yanjing Co., announced that it will accept investor research from September 17 to September 22, 2025, with the participation of the board secretary, Huang Teng, to address investor inquiries [1] - The industry is currently focused on a large-scale procurement organized by the state, which has raised concerns due to low bidding prices and the requirement for bidding companies to provide clear explanations [1]

Group 1: Market Overview - The A-share market has experienced a surge in new account openings since the initiation of the "924 market" trend, with 28.746 million new accounts opened from October 2024 to August 2025, and projections suggest that the total will exceed 30 million by September 2025 [1][2] - The trend shows a fluctuating increase in new accounts, peaking at 3.0655 million in March 2025, followed by a recovery in June to August after a dip in April and May [2][3] Group 2: Investor Composition - Individual investors are the primary contributors to the new account openings, while institutional accounts have also seen a rebound, with 65,100 new institutional accounts opened in the first eight months of 2025, marking a nearly 33% year-on-year increase [3][4] Group 3: Reasons for Account Opening Surge - The surge in new accounts is attributed to a combination of "asset scarcity" and the significant profit potential in the stock market, leading to a shift of funds from traditional savings to equities [4][5] - The decline in yields from traditional investment channels, such as ten-year government bonds and bank wealth management products, has diminished their attractiveness, while the Shanghai Composite Index has risen approximately 40% since the "924 market" began [4][5] Group 4: Shift to ETF Investments - There has been a notable shift in how residents are entering the market, with ETFs becoming a preferred investment vehicle over actively managed funds due to their product diversity, lower costs, and ease of access [6][7] - As of September 19, 2025, the total market size of ETFs reached approximately 5.31 trillion yuan, reflecting a growth of 2.45 trillion yuan and an increase of 85.36% since the "924 market" began [7] Group 5: Brokerage Firms' Performance - Leading brokerage firms have capitalized on the influx of new accounts, with several firms reporting significant increases in new account openings, such as Guotai Junan with approximately 1.55 million new accounts and CITIC Securities with over 700,000 [8][9] - The influx of new clients has also led to substantial asset growth, with firms like Dongfang Securities reporting a 90% increase in new clients and a 45% increase in assets brought in [8][9] Group 6: Competitive Advantage of Leading Brokerages - The competitive edge of top brokerage firms lies in their multi-channel customer acquisition strategies and comprehensive financial service capabilities, which enhance client retention and stability during market fluctuations [10]

Core Viewpoint - The photovoltaic glass industry is experiencing a recovery in profitability due to improved supply-demand dynamics and industry self-discipline measures aimed at reducing excessive competition [1][5]. Industry Overview - As of September 19, the inventory of photovoltaic glass reached 1.3 million tons, the lowest in nearly a year [1]. - The production capacity of photovoltaic glass was 12.9 million tons per day, with an industry operating rate of 51.59% as of the end of August [1]. - Photovoltaic glass prices have been rising since July, with average prices for 3.2mm and 2.0mm single-layer coated glass at 20.25 and 13.35 yuan per square meter, respectively, reflecting increases of 1.75 and 2.5 yuan per square meter since early July [1][2]. Market Dynamics - The "anti-involution" actions within the industry are key to driving price recovery, with several companies planning to collectively reduce production by 30% by July 2025 [1]. - The central government's policies are supporting these self-discipline efforts, aiming to eliminate low-price competition and promote product quality [1]. Company Performance - Major photovoltaic glass companies showed signs of recovery in Q2 2025, with Fuyao achieving a net profit of 155 million yuan, a 46% increase quarter-on-quarter, and a gross margin improvement of approximately 5 percentage points to around 16.7% [3]. - Qibin Group reported a net profit of 420 million yuan in Q2 2025, a 14% year-on-year increase, with revenue from photovoltaic glass business reaching 3.2 billion yuan, up 11% year-on-year [3]. Competitive Landscape - Leading photovoltaic glass companies are expected to demonstrate stronger resilience and profitability due to their scale, cost, and technological advantages [4]. - Fuyao and Xinyi Solar together hold over 50% market share, providing them with significant negotiating power in pricing and capacity adjustments [4]. Investment Outlook - There is optimism regarding the profitability and valuation recovery of leading companies as the anti-involution policies are implemented and capacity adjustments accelerate [5]. - Companies like Fuyao (601865.SH) and Qibin Group (601636.SH) are positioned to achieve both profitability and valuation recovery during the industry's resurgence [5].